Tag Archive for: central nervous system

Neuraxpharm reports another year of sustained growth and international expansion

/in

CNS specialist continues growth strategy across Europe and beyond, optimizing commercial efficiency and maintaining strong focus on innovation Barcelona, Spain and Düsseldorf, Germany – 14 November 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, marked the sixth anniversary since its rebranding as Neuraxpharm […]

Read more

Neuraxpharm expands operations into the Middle East

/in

Brings leading CNS products, including BRIUMVI® (ublituximab), to new territories Dubai, UAE, Barcelona, Spain and Düsseldorf, Germany – 1st October, 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the launch of Neuraxpharm Middle East to cover the six members of the Gulf Cooperation […]

Read more

Rare Disease Day 2024 – Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy

/in

Barcelona, Spain and Düsseldorf, Germany – 29 February, 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, and Minoryx Therapeutics, a late stage biotech company focused on the development of therapies for orphan central nervous system disorders, reaffirm their commitment on Rare Disease Day […]

Read more

Update on Regulatory Review of leriglitazone in the EU

/in

A re-examination for cerebral adrenoleukodystrophy (cALD) will be requested following a negative CHMP opinion Barcelona, Spain and Düsseldorf, Germany – 26 January, 2024 – Minoryx Therapeutics, a late stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders and Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused […]

Read more

Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510

/in

Synendos Therapeutics transitions to a clinical-stage biotech company developing innovative Endocannabinoid System (ECS) treatments for neuropsychiatric, neuroinflammatory and other Central Nervous System (CNS) disorders Clinical Trial will investigate the safety, tolerability and pharmacokinetics of Synendos’ first-in-class ECS modulator BASEL, Switzerland – 18 January 2024 – Synendos Therapeutics AG (Synendos), a world leader in innovative Endocannabinoid System […]

Read more